Cancer immunotherapy has emerged as a new approach to treat cancer that is promising to revolutionize cancer treatment and survival outcomes. Cancer immunotherapy utilizes the innate powers of the immune system to fight cancer, and with its advent we are witnessing long-lasting remissions, with minimal side effects, in some patients with advanced cancers. Are we finally entering an era in which cancer will become a manageable and even curable disease? Are we witnessing the beginning of the end of cancer?
Join us at “The Promise of Immuno-oncology” track, at IATI-Biomed, on May 24, as key opinion leaders from academia and industry present and discuss various approaches, aspects and trends in cancer immunotherapy, including immune checkpoint inhibitors, Chimeric Antigen Receptor (CAR) T-cell therapy, vaccines, Tumor Associated Macrophages (TAMs), combination therapy, biomarkers and more.
Come hear Arie Belldegrun, on “Engineered T cell Immunotherapy: The future is here”, at the IATI-Biomed 2016 Conference, May 24-26:
